Safety and Tolerability QAT370 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease

A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of an Efficacious Dose of QAT370 Compared to Open-label Tiotropium Bromide Following Once Daily Dosing for 7 Days in COPD Patients

This study will assess the safety and tolerability of QAT370 compared to tiotropium in patients with COPD.

Inclusion Criteria:

• Patients between 40 and 80 years of age with controlled COPD.
• Women must be surgically sterilized or postmenopausal. Additional birth control and post-menopausal information will be available at time of enrollment.
• Body mass index (BMI) must be within the range of 18 to 32 kg/m2

Exclusion Criteria:

• Participation in any interventional clinical investigation with 4 weeks of study start
• Blood loss or donation of 400 mL or more within 2 months of study start Significant illness (other than respiratory) within 2 weeks of study start
• Past medical personal or close family history of clinically significant ECG abnormalities
• Any medical condition that may interfere with exercise testing or that may make spirometry unsafe
• A known hypersensitivity to the drug.
• History of immunocompromise, including a positive HIV test result.
• History of drug or alcohol abuse within 12 months of study start
• Any condition that may compromise patient safety